Swiss Biotech Gnubiotics, Announces Global Launch of GNU100 the First Microbiome Specialty Ingredient for Companion Animal Gut Health

Gnubiotics Sciences SA is a Swiss biotech company pioneering the development of products from complex microbiota accessible carbohydrates (MACs) as specialty ingredients for the global animal and human nutrition markets. Gnubiotics announced its listing in the EU Feed Materials Register and commercial launch of its first-in class microbiome modulating prebiotic GNU100, for companion animal gut health. Gnubiotics’ GNU100 MAC is registered in Europe as an oligosaccharide-peptide complex with the objective to enhance microbiota restoration. As a result of its activity on specific commensals in the microbiome, GNU100 will also be studied to act as a weight control modulator.

LAUSANNE, Switzerland (PRWEB) April 12, 2019 -- Gnubiotics Sciences SA is a Swiss biotech company pioneering the development of products from complex microbiota accessible carbohydrates (MACs) as specialty ingredients for the global animal and human nutrition markets.

Gnubiotics announced its listing in the EU Feed Materials Register and commercial launch of its first-in class microbiome modulating prebiotic GNU100, for companion animal gut health. Gnubiotics’ GNU100 MAC is registered in Europe as an oligosaccharide-peptide complex with the objective to enhance microbiota restoration. As a result of its activity on specific commensals in the microbiome, GNU100 will also be studied to act as a weight control modulator.

GNU100 comprises of at least 30 different oligosaccharide structures that are functional mimics of Human Milk Oligosaccharides (HMOs). HMOs are oligosaccharides found naturally in animal and human breast milk and are key to the early development and maintenance of the immune system.

At Vitafoods Europe, Gnubiotics will host a presentation by Prof. Kelly Swanson of the University of Illinois-Urbana Champaign, titled “Modulatory Activity of Microbiota Accessible Carbohydrates” which will highlight GNU100 in vivo palatability data as well as the in vitro activity of GNU100 on key microbes beneficial to companion animal health Lactobacillus acidophilus, Akkermansia muciniphila and Bacteroides thetaiotaomicron.

“The global launch of GNU100 marks a milestone in our commitment to bringing the benefits of our pipeline of functional HMO mimics to companion animals,” said JP Kunz, CEO at Gnubiotics.

Through the combination of advanced high-precision chemistry and genomic technologies, Gnubiotics aims to expand nutritional solutions, to meet consumer expectations for effective, natural and healthier foods and supplements for their companion animal.

To learn more about how GNU100 can benefit your consumers, please visit Gnubiotics Sciences at Vitafoods Europe in Geneva Palexpo, May 7 – 9, 2019, at booth #K85
StartLab / Biopôle, Route de la Corniche, 5, Bat. SE-B Page 1 of 2 CH-1066 Epalinges

Media contact information – Gnubiotics Sciences SA. Jean Philippe Kunz, CEO Email: jpkunz(at)gnubiotics.com
Contact Information
Jean-Philippe Kunz
GNUBIOTICS
http://www.gnubiotics.com
+41 799069227

Online Web 2.0 Version
You can read the online version of this press release here.